Use of H19 Gene Regulatory Sequences in DNA-Based  Therapy for Pancreatic Cancer by Scaiewicz, V. et al.
Hindawi Publishing Corporation
Journal of Oncology
Volume 2010, Article ID 178174, 10 pages
doi:10.1155/2010/178174
Research Article
UseofH19GeneRegulatory SequencesinDNA-Based
Therapy for Pancreatic Cancer
V. Scaiewicz,1 V. Sorin,1 Y. Fellig,2 T. Birman,1 A.Mizrahi,1 J. Galula,1 R.Abu-lail,1
T. Shneider,1 P.Ohana,1 L.Buscail,3 A.Hochberg,1 andA.Czerniak4
1Department of Biological Chemistry, Institute of Life Sciences, The Hebrew University of Jerusalem, Edmond Safra Campus,
Givat Ram, Jerusalem 91904, Israel
2Department of Pathology, Hadassah University Hospital, Jerusalem 91120, Israel
3Institut National de la Sant´ ee td el aR e c h e r c h eM ´ edicale U531, Institut Louis Bugnard, Institut Federatif de Recherche-31,
Centre Hospitalier Universitaire Rangueil, 31403 Toulouse, France
4Department of Surgery “A”, Sheba Medical Center, Tel Hashomer 52621, Israel
Correspondence should be addressed to V. Scaiewicz, vscaiewicz@gmail.com
Received 22 June 2010; Accepted 13 September 2010
Academic Editor: Douglas S. Tyler
Copyright © 2010 V. Scaiewicz et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Pancreatic cancer is the eighth most common cause of death from cancer in the world, for which palliative treatments are not
eﬀectiveandfrequentlyaccompaniedbyseveresideeﬀects.WeproposeaDNA-basedtherapyforpancreaticcancerusinganonviral
vector, expressing the diphtheria toxin A chain under the control of the H19 gene regulatory sequences. The H19 gene is an
oncofetal RNA expressed during embryo development and in several types of cancer. We tested the expression of H19 gene in
patients, and found that 65% of human pancreatic tumors analyzed showed moderated to strong expression of the gene. In vitro
experiments showed that the vector was eﬀective in reducing Luciferase protein activity on pancreatic carcinoma cell lines. In
vivo experiment results revealed tumor growth arrest in diﬀerent animal models for pancreatic cancer. Diﬀerences in tumor size
between control and treated groups reached a 75% in the heterotopic model (P = .037) and 50% in the orthotopic model (P =
.007). In addition, no visible metastases were found in the treated group of the orthotopic model. These results indicate that the
treatment with the vector DTA-H19 might be a viable new therapeutic option for patients with unresectable pancreatic cancer.
1.Introduction
Pancreatic cancer is the eighth most common cause of death
from cancer in the world, with a very poor prognosis and a
5-year survival rate of about 3% [1, 2]. Due to late diagnosis
because of the lack of marked symptoms, less than 20% of
the patients are candidates for surgical resection—the only
known possible treatment to cure this disease. Most of the
patients present unresectable tumors and, because of the
natural aggressiveness of the disease, micro- and macro-
metastases are frequent in patients. Several clinical trials are
being conducted combining diﬀerent chemotherapies and
radiotherapies, but none has yet shown more than a 10-
month survival result [3, 4]. Given those facts, the need for
new and more eﬀective therapies is essential.
Our group previously reported the use of DNA-based
therapy for cancer treatment which drives the expression
of diphtheria toxin A chain by the regulatory sequence of
the H19 gene only into cancer cells [5, 6]. The human H19
gene is mapped at the short arm of chromosome 11, p15.5,
homologoustoaregionofmurinechromosome7[7].Itisan
imprinted gene, expressed from the maternal allele in several
tissues during embryo development and repressed right after
birth [8]. H19 gene was shown to be re-expressed in several
cancer tissues derived from those tissues which expressed the
gene during embryonic development [9], such as bladder
cancer [10], hepatocellular carcinoma [11], adrenocortical
tumors [12], choriocarcinoma [13], colorectal cancer [14],
ovarian carcinoma, and lung carcinoma [15]. H19 RNA
shares all known characteristics of messenger RNA but has2 Journal of Oncology
no known protein product [16]. H19 gene was also shown
to play an important role in tumor growth; its expression
caused diﬀerential expression of other genes [17]. It was
demonstrated that oncogenes, tumor suppressor genes, and
angiogenesis factors like TNF-α and NFκB are regulated by
the H19 gene [17].
The present work tested the feasibility of using the reg-
ulatory sequences of the H19 gene to express the diphtheria
toxin A subunit for a DNA-based treatment for pancreatic
cancer.
2.MaterialsandMethods
2.1. Gene Expression
2.1.1. In Situ Hybridization. Tissue samples were prepared as
described previously [13]. ISH was performed as described
by Ariel et al. [11], using the digoxigenin labeled H19 RNA
probe or by a modiﬁcation of this method using H19-
LNA (locked nucleic acid) Dig-labeled probe synthesized at
Exiqon (See Table SA in Supplementary Mateial available
online at doi:10.1155/2007/69141).
2.1.2. RT-PCR Analyses. Total RNA was extracted from
cell lines or frozen tissue, using TRI Reagent Solution,
following manufacture’s instructions (Sigma-Aldrich Israel
Ltd., Rehovot, Israel). cDNA was synthesized starting from
2μg total RNA using the M-MLV Reverse Transcriptase kit
following manufacturerr’s instructions (Promega, Madison
WI, USA). PCR reactions were carried out using GoTaq
Green Master Mix (Promega), starting from 2μlc D N Ai na
ﬁnal volume of 25μl, according to the manufacture instruc-
tions, in the presence of 0.1μg/μlo fe a c ho ft h ef o r w a r da n d
thereverseprimers.Primersdesignationsequences,andPCR
conditions are detailed in Supplement Table A. The integrity
of the cDNA was assayed by PCR analysis of the ubiquitous
beta actin, which was used as internal control. As negative
control for all PCR analysis, the reaction was carried out
using water in the absence of cDNA.
2.2. Sequencing. For analysis of hamster H19 gene expres-
sion, RT-PCR was performed using 2 diﬀerent sets of
primers designed for mouse H19 gene. The resulting bands
in the gel were puriﬁed using the Wizard SV Gel and
PCR Clean-Up System kit, following the manufacture’s
instruction. The puriﬁed PCR product was sent to The
Center for Genomic Technologies, The Hebrew University of
Jerusalem. Sequences were veriﬁed by BLAST analysis using
two diﬀerent databases, Ensembl (http://www.ensembl.org/)
and NCBI (http://www.ncbi.nlm.nih.gov/), and by sequence
alignment using MAFFT version 6 (http://align.bmr.kyushu-
u.ac.jp/maﬀt/online/server).
2.3. Cell Culture. The diﬀerent cell lines used in this investi-
gation were chosen because of their diﬀerences in the level
of H19 gene expression and their response to transfection
procedure. Human pancreatic adenocarcinoma cell lines
CRL-1687, CRL-2119, CRL-1997, and CRL-2547 and ductal
adenocarcinoma cell line CRL-1469 were obtained from
the American Type Culture Collection (ATCC; Rockville,
MD, USA) and cultured in 90% DMEM-F12 medium and
10% Fetal Bovine Serum (FBS). The hamster pancreatic
ductal carcinoma cell line PC.1-0 was kindly provided
by Dr. Buscail L. (Institut National de la Sant´ ee td el a
Recherche M´ edicale U531, Institut Louis Bugnard, Institut
Federatif de Recherche-31, Centre Hospitalier Universitaire
Rangueil, 31403 Toulouse, France) and was cultured in
90% RPMI-1640 medium supplemented with 10% FBS.
Antibiotic solution (penicillin (180 units/ml), streptomycin
(100μg/ml), and amphotericin-B (0.2μg/ml)) were added to
all medium solution.
2.4. Plasmids and In Vitro Experiments. The reporter plas-
mids and the DTA-H19 construct were prepared as previ-
ously described [5, 6]. A total of 7–9 × 105 cells/well were
grown overnight in a twelve-well Nunc multidish. Cells were
cotransfected with 2μg of the Luc-SV40 reporter vector and
increasing concentrations of the DTA-H19 vector using the
transfectant jetPEI (Polyplus, Illkirsh, France) according to
manufacturer’sinstructions(N/P =5).Theluciferaseactivity
in the cotransfected cells (DTA-H19 and Luc-SV40 vectors)
was compared to that obtained in the cells transfected with
Luc-SV40 only, in order to determine the cytotoxic eﬀect of
the DTA-H19 plasmid.
2.5. In Vivo DNA-Based Therapy
2.5.1. Heterotopic Model for Pancreatic Cancer. Conﬂuent
cells were trypsinized and resuspended in PBS X1. A ﬁnal
volume of 100μl of cell suspension was injected subcuta-
neously into athymic nude mice (5–6 weeks old and 20–
30grs) purchased from Harlan (Zeist, The Netherlands).
After tumor reached an approximated size of 3mm ×
3mm, 3 treatments were given, with a 2-day interval
between each treatment, by direct injection into the tumor.
Treatment consisted of 25μg plasmid (DTA-H19 for treated
group and Luc-H19 for control group) mixed with the
nonviral transfectant polyethylenimine (Polyplus) (N/P = 6)
diluted in 50μl of 5% w/v glucose (prepared according to
manufacturer’s instructions). Animals were sacriﬁced 3 days
after the third treatment; tumors were excised for ex vivo
measurements and for pathology and molecular studies.
2.5.2. Orthotopic Model for Pancreatic Cancer. The following
pancreatic cancer animal model was based on previous stud-
ies [18, 19]. 5–6-week-old male Syrian golden hamsters (70–
80grs) were purchased from Harlan and used to generate
the orthotopic model. After anesthetization by subcutaneous
injection of Ketamine and Xylazine (85mg/kg and 15mg/kg,
resp.), the pancreas was surgically exposed, and 25μlo fc e l l
suspension containing 250,000 PC.1-0 cells in PBS X1 were
injectedsubcapsularlyintothepancreasusingacatheterwith
a 27-gauge needle. Tumors reached a treatable size on day 7,
and metastases were visible on day 9 following cell injection.
After tumors were generated, the animals bearing the
pancreatic tumors were treated at days seven and nine fol-
lowing cell injection. On day eleven, animals were sacriﬁced.Journal of Oncology 3
(a) (b)
Figure 1:ISHofwell-diﬀerentiatedpancreaticcarcinomafromtwodiﬀerentpatients.(a)DetectionofH19transcriptusingDig-labeledH19
LNA-DNAprobebyISH.Thearrowpointstothepositivehybridization signalswithinthecytoplasmofthecancer cells (10Xmagniﬁcation).
(b)DetectionofH19transcriptusingDig-labeledH19LNA-DNAprobebyISH.Thearrowpointstothepositivehybridizationsignalswithin
the cytoplasm of the cancer cells (20X magniﬁcation). Tissue was later stained using Hematoxylin and Eosine.
The treatments were given under anesthesia, consisting of
an intratumoral injection of 50μgo fD N Av e c t o r( L u c -
H19 for the control group and DTA-H19 for the treated
group) resuspended in 25μl of saline solution. Before each
treatment and before sacriﬁce, tumor sizes were measured
using a caliber, and abdominal cavity was searched for
visible metastases. Tumors were excised and their ex vivo
dimensions were recorded following sacriﬁce and tumor
measurement in vivo. The tumors were cut in the middle;
one half of each tumor was ﬁxed in formalin, processed,
and embedded in paraﬃn for pathology studies, and the
other half was frozen in liquid nitrogen for further molecular
analysis. All experiments were performed according to the
rules of the Animal Ethics Committee.
3. Results
3.1. H19 Expression in Human Pancreatic Cancer. Human
pancreatic tumor samples from 49 patients were examined
for H19 expression by ISH. Results showed that 65% of the
tested samples were positive for H19 expression (Figures 1(a)
and 1(b)).
3.2. H19 Expression in Cell Lines. Three of the analyzed
cell lines (CRL-2547, CRL-1687, and CRL-1469) showed
high level of H19 expression (Figure 2(b), lanes 2 and
3a n dFigure 2(a), lane 2, resp.), whereas the other two
cell lines (CRL-2119 and CRL-1997) showed low levels of
H19 expression (Figure 2(b), lanes 4 and 5, resp.). H19
expression was also analyzed on PC.1-0 cells, a hamster
pancreatic carcinoma cell line. Since there is no report of
the hamster’s H19 gene sequence at the gene databases
Ensembl and NCBI, primers designed originally for human
and murine known H19 sequence were tested to determine
H19 RNA level in hamster PC.1-0 cells. A faint band was
visualized when primers designed originally for mouse H19
gene sequence were used (Figure 2(c), middle panel, lane
3). Previous studies showed that H19 gene expression may
be induced by hypoxia and/or serum starvation conditions
and that the H19 gene may play a role in tumorogenesis
[17, 20]. Therefore, the level of H19 RNA in PC.1-0 was
determined by RT-PCR extracted from cells cultured under
hypoxia conditions for four hours, and also in total RNA
extracted from tumors generated in athymic nude mice
back by injecting 2∗106 PC.1-0 cells (cells injected were
cultured under normal conditions). When amplifying total
RNA from cells cultured under hypoxia, a weak band was
visualized using the set of primers H19 mouse (Figure 2(c),
lane 4, middle panel; primers 454bp Supplement Table A).
On the other hand, when RNA extracted from the PC.1-0
developedtumorswasanalyzed,strongbandswerevisualized
using the same set of primers (Figure 2(c), lane 5, upper
and middle panel). These strong bands were puriﬁed and
sequenced. BLAST analysis and sequences alignment showed
high homology between the PCR products and the available
sequences of mouse and human on gene databases (data not
shown). Despite the high homology between the sequences,
further analysis must be performed in order to assure that
the sequence corresponds indeed to the hamster H19 RNA.
3.3. DTA-H19 Vector Eﬃcacy: In Vitro Studies. In order to
test the in vitro therapeutic potential of DTA-H19 plasmid,
the human pancreatic carcinoma cells CRL-1687, CRL-2119,
CRL-1997, CRL-2547, and CRL-1469 and hamster pancre-
atic ductal carcinoma cell line PC.1-0 were cotransfected
with 2μg of Luc-SV40 at the indicated concentrations of
DTA-H19 plasmids (Figure 3). Luciferase activity was mea-
sured 48 hours after transfection, and data was normalized
to total protein per well. The toxic eﬀect was calculated
as the relative luciferase activity in the cotransfected cells
compared to the activity in cells transfected only with the
Luc-SV40 plasmid. The results showed that the DTA-H19
vector was eﬀective in reducing the Luciferase activity in
all the cell lines and that there is a dose-response eﬀect
(Figure 3). Exogenous H19 regulatory sequence activity was
assayed by expressing the luciferase gene under the control
of H19 regulatory sequences (Luc-H19 plasmid). Results
showed that the cytotoxic eﬀect of H19-DTA observed in4 Journal of Oncology
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Figure 2: H19 RNA level in human and hamster pancreatic carcinoma cell lines. (a) Lane 1: 100bp marker, Lane 2: CRL-1469 cells, Lane 3:
PC.1-0 hamster cells. (b) Lane 1: 100bp marker, Lanes 2–5: CRL-2547, CRL-1687, CRL-2119, and CRL-1997 human pancreatic carcinoma
cells,respectively.(c)Lane1:100bpmarker;Lane2:mousecontrol;Lane3:PC.1-0cellsculturedundernormoxiaconditions;Lane4:PC.1-0
cells cultured under hypoxia condition for 4 hours; Lane 5: tumors generated by PC.1-0 cells injection into nude mice back; Lane 6: negative
control, no cDNA is present in the reaction mixture. The upper and the middle panels show the 228bp and the 454bp PCR products,
respectively, obtained using two diﬀerent primers (H19-mouse 228 and H19-mouse 454 as described in Supplementary data, Table A). The
lower panel indicates the 400bp β-actin internal control.
the diﬀerent cell lines is directly correlated to the luciferase
activity expressed from the Luc-H19 plasmid (Figure 3).
3.4. DTA-H19 Treatment in Two Diﬀerent Animal
Models of Pancreatic Cancer
3.4.1. Heterotopic Model. Tumors were generated into
athymic nude mice back by subcutaneous injection of CRL-
1469 cells and then treated with DTA-H19 (n = 7) or Luc-
H19 (n = 8, control group) plasmid by direct injection
into the tumor. Results showed that treatment with DTA-
H19 resulted in an arrest of tumor growth, leading to
a relative maintenance of tumor volume (Figure 4(a)). A
signiﬁcant diﬀerence in tumor growth progression between
the two groups was found, indicating that the growth of
the DTA-H19 treated group was arrested (P-value = .036).
This observation was conﬁrmed by the ﬁnal ex vivo tumor
volume, which showed to be signiﬁcantly smaller for the
DTA-H19 group as compared to the control group (P-value
= .038) (Figure 4(b)).
Similar results were obtained when the model was gener-
atedbyinjectingCRL-2547cells(P-value< .1)(Figure 4(c)).
3.4.2. Othotopic Model. A hamster model of pancreatic
cancer was developed to evaluate the therapeutic eﬃcacy of
DTA-H19 for this indication. Seven days after cell implanta-
tion,alltheanimalspresentedvisibleandmeasurabletumors
in the pancreas. The relevance of this orthotopic pancreatic
carcinoma animal model was tested by studying the expres-
sion of the H19 gene which is a prerequisite to evaluate
the therapeutic potential of the toxin expression vector in
this animal model. All the analyzed samples from tumors
generated in the pancreas showed high H19 expression when
tested by RT-PCR (Figures 5(d) and 5(e)), signifying that
our model was suitable for testing the DTA-H19 eﬃcacy
in vivo. Following H19 expression conﬁrmation, histological
studies were performed in order to determine if the tumors
were compatible with pancreatic carcinoma. Histopathology
analysis detected adenocarcinoma in the pancreas (Figures
5(a)–5(c)). All the tumors presented necrotic areas which
were detected on the center of each tumor, caused by poor
oxygen and nutrients supply (Figure 5(b)).
Seven days after cell injection, 100% (n = 16) of the ani-
mals presented a single tumor in the pancreas. The average
sizeofthetumorwas0.019cm3,andsomeanimalspresented
possible metastases. The animals were divided into 2 groups,
the ﬁrst was treated with 50μg of DTA-H19 plasmid and
the second group with Luc-H19 plasmid (control group).
The treatments were given at days 7 and 9 following tumor
cellsinjection.Asexpected,DTA-H19treatmentwaseﬀectiveJournal of Oncology 5
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Figure 3: Reduction of Luciferase activity in human and hamster pancreatic carcinoma cell lines due to cotransfection with the DTA-H19
vector. The therapeutic potential of the DTA-H19 vector in diﬀerent cell lines was measured as a reduction of Luciferase activity. (a) 90000
cells/well were cotransfected with 3μg of Luc-SV40 plasmid and the indicated amounts of DTA-H19. The luciferase assay was performed 48
hours after transfection. (c) 70000 cells/well were cotransfected with 3μg of Luc-SV40 plasmid and the indicated concentrations of DTA-
H19. Transfection experiments were stopped after 24 hours, and reporter gene activity was assessed. The reduction in the Luc-SV40 activity
inthecotransfectedcellswascomparedtocellstransfectedwithLuc-SV40aloneforeachcellline.BargraphsrepresenttherelativeLuciferase
activity of the H19 promoter when cells were transfected with Luc-H19 plasmid.6 Journal of Oncology
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Figure4:Heterotopicmodelforpancreaticcancer.(a)AveragetumorvolumeofLuc-H19group(n = 8)andDTA-H19group(n = 7)during
the experiment using CRL-1469 cells. Treatments were administrated on days 0, 3, and 6 by direct intratumoral injection after subcutaneous
implantation of human pancreatic carcinoma cells in the back of nude mice. Three days after the last treatment, the animals were sacriﬁced.
(b) Average of ex vivo tumor volume at the end of the experiment, tumors generated using CRL-1469 cells. (c) Tumor Growth Progression
of Luc-H19 (n = 5) and DTA-H19 (n = 5) groups, in experiment using CRL-2547 cell line.
in inhibiting the tumor growth compared with the Luc-H19
treated tumors. While the control group showed a greater
than 200% increment in tumor size, the DTA-H19 group
showed approximately 100% (P < .03) (Figure 6(a)). At the
end of the experiment, the tumors were excised and their ex
vivo size was determined. A signiﬁcant diﬀerence on tumor
size was detected when comparing DTA-H19 tumors to the
control. The ex vivo tumor volume average of the DTA-
H19 treated group was almost half that of the control group
(P < .0075) (Figures 6(b) and 6(c)).
The level of DTA transcript was monitored by RT-PCR
analyses (Figure 7). All the samples showed the presence of
DTA transcript verifying that the intratumoral injection of
the plasmid leads to transfection and expression of the DTA
gene.
In order to test the systemic toxicity of DTA-H19,
diﬀerent organ samples were collected from animals treated
with the vector at terminal sacriﬁce and subjected to
histopathology examination. No gross or microscopic sig-
niﬁcant alterations were noted in the following organs:
pancreas, liver, lung, bowel, spleen, heart, kidney, adrenal
gland, lymph-node, salivary glands, gall-bladder, urinary-
bladder, and brain (data not shown).
Although treatment with naked DNA proved to be
suﬃcient for inhibiting tumor growth progression, we
tested if the use of a transfection enhancer reagent such
as PEI could improve the eﬃcacy results. According to the
developed animal model described previously, PC.1-0 cells
were injected into the pancreas. On day 7, when tumors
were visible, they were treated with 100μl of a complex
containing 50μg of DTA-H19 plasmid and in vivo PEI
(prepared according to manufacturer’s instructions). This
treatment was repeated on day 9, and animals were sacriﬁced
on day 11. The results obtained showed that no signiﬁcant
improvement in the therapeutic eﬀect was found when PEI
was used as a carrier for delivering the plasmid as compared
to that obtained using naked DNA (data not shown).
As mentioned above, metastases occurrence was also
analyzed during the present experiment. Metastases were
visible mostly on day 9, after the ﬁrst treatment, while few
animals showed metastases on day 7. All the animals in the
control group showed multiple visible metastases at the end
of the experiment, whereas 70% of the animals treated with
DTA-H19 did not show visible metastases, and the number
ofmetastasespresentinthoseanimalswassigniﬁcantlylower
(Table 1).Journal of Oncology 7
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Figure 5: Histopathology analyses and H19 transcript detection in orthotopicaly induced tumors in the pancreas. (a) and (b) Both pictures
show poorly diﬀerentiated carcinoma. The square in picture (a) delimits the malignant tissue; the circled area in picture (b) corresponds
to necrotic interface (X20 original magniﬁcation for picture (a), X40 original magniﬁcation for picture (b). (c) Interface pancreatic acini
(right), neoplasm (left), and desmoplastic reaction (middle) (X10 original magniﬁcation). Pictures were taken from paraﬃns e c t i o n sa n d
correspond to Giemsa stain. (d)–(f) Total RNA was extracted from frozen pancreatic tumors generated by intracapsular injection of PC.1-0
cells into hamsters pancreas. Lane 1: 100bp marker, Lane 2: mouse control RNA, Lane 3: RNA extracted from tumor generated in the head
of the pancreas, Lanes 4 and 5: RNA extracted from two diﬀerent tumors generated in the pancreas tail in two diﬀerent animals. (d) PCR
products using primers H19 mouse 454. (e) PCR products using H19-mouse 228 primers. (f) Internal control β-actin mRNA.
4. Discussion
The present study proposes a successful approach for the
diﬀerential killing of pancreatic cancer cells, without aﬀect-
ing the surrounding normal cells. This approach consists of
a DNA-based therapy expressing a toxin under the control
of regulatory sequences of a diﬀerentially expressed gene,
the H19 gene. It was previously demonstrated that the
DTA-H19 construct was able to kill tumor cells both in
vitro and in vivo in animal models for bladder cancer and
colorectal liver metastases [5, 6]. This toxin vector was used
in order to kill pancreatic cancer cells either in culture or
in tumors developed in heterotopic and orthotopic animal
models of pancreatic cancer. We successfully demonstrated
by ISH analysis that the H19 gene is expressed in 65% of
the analyzed human pancreatic cancer samples (n = 49,
Figure 1), indicating that treatment of human pancreatic
cancer with the DTA-H19 is very likely to be eﬀective in this
disease.
H19 promoter activity was analyzed in all human and
hamstercelllinesusingaplasmidcarryingtheluciferasegene
under the control of H19 regulatory sequence. A relatively
high activity of the regulatory sequences was detected in all
the tested cell lines, and this activity was correlated with
the cytotoxic eﬀect observed when using these sequences
for driving the expression of the diphtheria toxin A chain
(Figure 3). The eﬀect of the DTA-H19 plasmid cotransfected
into cells with a second plasmid which encodes the luciferase
gene under the control of the SV40 regulatory sequence
caused inhibition of the luciferase activity at a dose-response
manner in all the studied cell lines (Figure 3). The highest
amountoftheDTA-H19plasmidusedincotransfectionwith
Luc-SV40 construct was about 40 times lower than that of
the Luc-SV40 plasmid. Therefore, the observed eﬀectis more8 Journal of Oncology
0
50
100
150
200
250
T
u
m
o
r
g
r
o
w
t
h
p
r
o
g
r
e
s
s
i
o
n
(
%
)
Luc-H19 DTA-H19
(a)
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
T
u
m
o
r
v
o
l
u
m
e
(
%
)
Luc-H19 DTA-H19
(b)
(c)
Figure 6: Eﬀect of DTA-H19 treatment in Tumor Growth Progression and ex vivo tumor size on the orthotopic pancreatic carcinoma
in the hamster. (a) Average of tumor growth progression of the DTA-H19 (n = 9) and Luc-H19 (n = 7) treated groups calculated as the
ratio of tumor size at the end of the experiment (day 11 after cells implantation) compared to the size before treatment (day 7 after cells
implantation). (b) Average of ex vivo tumor volume of the treated (DTA-H19) and control group (Luc-H19) measured after sacriﬁce (day
11). (c) The left picture corresponds to a tumor treated with DTA-H19 plasmid, and the right picture corresponds to a tumor from the
control group.
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Figure 7: DTA expression in tumors samples. Total RNA was
extracted from frozen pancreatic tumors treated with DTA-H19
plasmid. DNase-treated RNA and nontreated RNA samples were
analyzed by RT-PCR for DT-A transcript level. Lane 1: 100bp
marker, Lanes 2 and 4: PCR products from DNase-treated RNA,
Lanes 3 and 5: PCR products from nontreated RNA, Lane 6:
negative control, no cDNA is present in the reaction mixture. The
upper panel shows the 468bp DT-A product, and the lower panel
shows the β-actin internal control.
likely due to the cytotoxic eﬀect of the DTA-H19 plasmid
expressionandnottheresultofcompetitionbetweenthetwo
plasmids for the entry into the cell. These results lead us to
test the toxic eﬀect of the plasmid in vivo.
Table 1: Metastases observation developed in the hamster ortho-
topic pancreatic carcinoma model. Animals presenting pancreatic
tumors were treated twice with DTA-H19 or Luc-H19 plasmids.
Before each treatment, abdominal cavity was searched for metas-
tases in both groups, the treated group DTA-H19 (n = 9) and the
control group (n = 7). Most metastases appeared visible on day 9.
Group
Animals with
metastasis on
day 7/total
Animals with
metastasis on
day 9/total
Animals with
metastasis on day
11/total
DTA-H19 0/9 3/9
3/9 Metastases in
liver, stomach, or
intestine (n ≤ 2)
Luc-H19
(control group) 1/7 4/7
7/7 Multiple
abdominal
metastases (n>3)
We tested the cytotoxic eﬀect of the therapeutic vec-
tor both in a heterotopic and an orthotopic model for
pancreatic cancer which are complementary and allow
the study of tumors with distinctive histopathologies. The
results obtained in the heterotopic model using CRL-1469
cells showed a signiﬁcant diﬀerence in TGP (P = .036)
between the DTA-H19 treated group and the control group.Journal of Oncology 9
These results were conﬁrmed by the reduction in tumor
size ex vivo, where the average tumor size of the DTA-H19
group was almost 1/3 the size of the control group (P = .037)
(Figure 4). Furthermore, when using a diﬀerent cell line to
generate the tumors, CRL-2547 cells, similar results were
obtained, corroborating that the treatment with DTA-H19
was eﬀective in arresting tumor growth.
We successfully developed an orthotopic animal model
for pancreatic cancer. The fact that all the animals developed
a similar size of tumors after PC.1-0 cell injection ensured its
reproducibility. H19 expression was previously determined
in the developed tumors by RT-PCR analyses in order to
validate the use of this animal model in evaluating the
potential therapeutic eﬀect of the toxin vector. High levels of
H19 gene expression were detected in the developed tumors
even though no expression was detected in cultured cells
(Figure 5), which is in agreement with previous observations
establishing that H19 gene expression may be induced
by hypoxia and/or serum starvation conditions developed
following injection of tumor cells into the animal tissue [17].
Animals presenting pancreatic tumors were then treated
with either DTA-H19 plasmid or the control plasmid (Luc-
H19) administrated twice by direct injection into the tumor.
We demonstrated that although the treatment consisted
of an injection of naked DNA into the tumor, the vector
indeed entered the cells and the H19 sequence was eﬀective
in leading to the DT-A gene expression (Figure 7). It was
previously observed that no signiﬁcant diﬀerence in eﬃcacy
was found when comparing the use of naked DNA to
DNA-PEI when administrated by direct injection into the
tumor [6].
The activity of the H19 promoter was demonstrated
in the human and hamster pancreatic tumor cells tested,
leading to DTA expression (Figures 2 and 3). Therefore,
inhibition of the growth of DTA-H19 treated tumors in
the hamster results from the action of the DTA produced
(Figure 6(a)). Intratumoral injection of the toxin vector
under the control of the H19 regulatory sequences induced
a 50% decrease in the median tumor volume as compared to
that of the tumor treated with the Luc-H19 vector (Figures
6(b) and 6(c)). Although the tumors were not completely
ablated, the treatment with the toxin vector signiﬁcantly
reduced the growth rate of the DTA-H19 treated tumors as
compared to the control group. We described the appearance
ofvisiblemetastasesonday9aftercellinjection.Weobserved
that after DTA-H19 treatment, 67% of the treated animals
did not present visible metastases. The number of metastases
found in the rest of the treated group (33%) was signiﬁcantly
lower and more localized than those of the control group.
These results indicate that the lack of visible metastases in
2/3 of the animals is related to the reduction of tumor
progression in the DTA-H19 treated animals. Metastases
d e v e l o p e di nt h et o x i n - t r e a t e dg r o u pm a yh a v eb e e na l r e a d y
present before the ﬁrst treatment, as micrometastases, and
therefore their growth was not completely prevented by the
intratumoraltreatment.Successfultreatmentdependsonthe
activity of the tumor-speciﬁc promoter. The H19 promoter
is known to be diﬀerentially activated in various tumor types
and to show none or undetectable activity in normal tissue
[5, 6]. The presented results lead us to advocate a new DNA-
based treatment for pancreatic cancer, inducing cytotoxic
eﬀect in cancer cells by intratumoral injection of a naked
DNA vector containing the DT-A gene under the control of
H19 regulatory sequences for human pancreatic cancer.
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